News | Checkpoint inhibitors and COVID-19 mortality; HCC rates slow in cities, continue to climb in rural areas
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest: HCC rates slow in cities, continue to climb in rural areas: Risk factors for severe immune-related AEs identified:
Contact Blood & Cancer at podcasts@mdedge.com
